Navigation Links
Shimadzu's New DSC-60 Plus Series Differential Scanning Calorimeters Offer High-Sensitivity Analysis in Polymer, Food and Pharmaceutical Applications
Date:4/18/2013

Columbia, Maryland (PRWEB) April 18, 2013

Shimadzu Scientific Instruments has introduced the DSC-60 Plus Series differential scanning calorimeters, indispensable thermal analyzers for materials characterization. The DSC-60 Plus Series offers the high-sensitivity analysis and easy operation required for the development of high-functioning new materials in the food, polymer and pharmaceutical industries.

As high-performance, general-purpose differential scanning calorimeters, the DSC-60 Plus Series offers high sensitivity and high resolution during analysis. Its new detector and unique furnace construction achieve a stable baseline across the entire measured temperature range (-140 to 600° C), as well as top-class temperature sensitivity. The eco-friendly furnace achieves more than 20 percent lower energy consumption when heating from room temperature.

A cooling chamber comes installed as standard on the DSC-60 Plus Series. The liquid-nitrogen cooling chamber permits easy measurements without the need for special accessories. Further, it achieves a cooling rate of 10° C/minute at -100° C. Its sample loading temperature function enables quick sample change without dewfall during sequential analysis.

The DSC-60A Plus model features a built-in compact autosampler, which permits automated measurement, analysis and report printout for up to 24 loaded samples. It improves the efficiency of screening during product development, as well as the efficiency of quality control activities.

Additionally, the DSC-60 Plus Series complies with various analytical laboratory regulations, including the U.S. Food and Drug Administration’s 21 CFR Part 11.

For more information about the DSC-60 Plus Series, visit http://www.ssi.shimadzu.com/products/product.cfm?product=dsc60Plus.

About Shimadzu Scientific Instruments Inc.
Shimadzu Scientific Instruments (SSI) is the American subsidiary of Shimadzu Corp., headquartered in Kyoto, Japan. Founded in 1875, Shimadzu is a $3 billion multinational corporation with three major divisions: Medical Diagnostics, Aerospace/Industrial and Analytical Instruments. In the United States, SSI has a network of more than 50 locations providing local and regional sales, service and technical support. Visit http://www.ssi.shimadzu.com for more information.

###

Read the full story at http://www.prweb.com/releases/2013/4/prweb10650226.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
2. Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising
3. InnoPharma Completes $15 Million Series A Financing
4. Aratana Therapeutics Completes $15 Million Series B Financing
5. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
6. Roka Bioscience Secures $47.5 Million in Series D Financing
7. Auxogyn Completes $20 Million In Series A Funding
8. Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
9. NeuroPhage Extends Series B to $21.4M
10. Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin
11. Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... 23, 2016 A person commits a crime, and ... to track the criminal down. An outbreak of ... Drug Administration (FDA) uses DNA evidence to track down the ... Sound far-fetched? It,s not. The FDA has increasingly used a ... of foodborne illnesses. Put as simply as possible, whole genome ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology:
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential ... use of DNA technology to an industry that is ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
(Date:3/21/2016)... WAKEFIELD, Massachusetts , March 22, 2016 ... and facial recognition with passcodes for superior security ... MESG ), a leading provider of secure digital communications ... pilot their biometric technology and offer enterprise customers, particularly ... provide secure facial recognition and voice authentication within a ...
Breaking Biology News(10 mins):